Figures & data
Figure 1. Characteristics of the different formulations of metformin: delayed release compared with extended release and immediate release. GI: gastrointestinal; GLP-1: glucagon-like peptide-1; BID: twice a day; TID: three times a day.
![Figure 1. Characteristics of the different formulations of metformin: delayed release compared with extended release and immediate release. GI: gastrointestinal; GLP-1: glucagon-like peptide-1; BID: twice a day; TID: three times a day.](/cms/asset/9055694d-af89-4bd1-87c2-718cc6c82ebf/ieop_a_1149166_f0001_b.gif)
Table 1. Main results (changes from baseline) of a 12-week, phase 2, placebo-controlled, dose-ranging study comparing metformin DR 600, 800, or 1,000 mg administered once daily; blinded placebo; or unblinded metformin XR 1,000 or 2,000 mg once-daily (reference) in patients with T2D (drug-naïve or after a 14–17 day wash-out) and an estimated glomerular filtration rate 60 ml/min/1.73 m2. Adapted from data reported in reference.[Citation13]